Biotricity (BTCY) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

BTCY Stock Forecast

Biotricity stock forecast is as follows: an average price target of $4.00 (represents a 981.08% upside from BTCY’s last price of $0.37) and a rating consensus of 'Buy', based on 1 wall street analysts offering a 1-year stock forecast.

BTCY Price Target

The average price target for Biotricity (BTCY) is $4.00 based on 1-year price targets from 1 Wall Street analysts in the past 3 months, with a price target range of $4.00 to $4.00. This represents a potential 981.08% upside from BTCY's last price of $0.37.

BTCY Analyst Ratings

Buy

According to 1 Wall Street analysts, Biotricity's rating consensus is 'Buy'. The analyst rating breakdown for BTCY stock is 0 'Strong Buy' (0.00%), 1 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Biotricity Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Jul 05, 2023	Kevin Dede	H.C. Wainwright	$4.00	$2.67	49.66%	981.08%

Row per page

Go to

The latest Biotricity stock forecast, released on Jul 05, 2023 by Kevin Dede from H.C. Wainwright, set a price target of $4.00, which represents a 49.66% increase from the stock price at the time of the forecast ($2.67), and a 981.08% increase from BTCY last price ($0.37).

Biotricity Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	-
Avg Price Target	-	-	-
Last Closing Price	$0.37	$0.37	$0.37
Upside/Downside	-100.00%	-100.00%	-100.00%

In the current month, the average price target of Biotricity stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Biotricity's last price of $0.37. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Jul 05, 2023	H.C. Wainwright	Buy	Buy	Hold

Row per page

Go to

Biotricity's last stock rating was published by H.C. Wainwright on Jul 05, 2023. The company gave BTCY a "Buy" rating, the same as its previous rate.

Biotricity Financial Forecast

Biotricity Revenue Forecast

	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21
Revenue	-	-	-	-	$2.89M	-	$2.74M	$2.46M	$2.38M	$2.06M	$2.15M	$1.76M	$1.81M	$1.93M
Avg Forecast	$3.62M	$3.20M	$3.20M	$3.00M	$3.30M	$3.10M	$2.60M	$2.40M	$2.54M	$2.19M	$2.11M	$2.10M	$1.81M	$1.60M
High Forecast	$3.62M	$3.20M	$3.20M	$3.00M	$3.30M	$3.10M	$2.60M	$2.40M	$2.54M	$2.19M	$2.11M	$2.10M	$1.81M	$1.60M
Low Forecast	$3.62M	$3.20M	$3.20M	$3.00M	$3.30M	$3.10M	$2.60M	$2.40M	$2.54M	$2.19M	$2.11M	$2.10M	$1.81M	$1.60M
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1
Surprise %	-	-	-	-	0.88%	-	1.05%	1.02%	0.94%	0.94%	1.02%	0.84%	1.00%	1.21%

Biotricity's average Quarter revenue forecast for Dec 23 based on 1 analysts is $3.00M, with a low forecast of $3.00M, and a high forecast of $3.00M. BTCY's average Quarter revenue forecast represents a 3.76% increase compared to the company's last Quarter revenue of $2.89M (Sep 23).

Biotricity EBITDA Forecast

	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1
EBITDA	-	-	-	-	$-2.32M	-	$-2.23M	$-4.36M	$-4.47M	$-4.53M	$-5.15M	$-3.02M	$-6.52M	$-5.00M
Avg Forecast	$-3.40M	$-3.01M	$-3.01M	$-2.82M	$-3.10M	$-2.91M	$-2.44M	$-2.26M	$-2.39M	$-2.06M	$-1.98M	$-1.98M	$-1.70M	$-3.69M
High Forecast	$-3.40M	$-3.01M	$-3.01M	$-2.82M	$-3.10M	$-2.91M	$-2.44M	$-2.26M	$-2.39M	$-2.06M	$-1.98M	$-1.98M	$-1.70M	$-2.95M
Low Forecast	$-3.40M	$-3.01M	$-3.01M	$-2.82M	$-3.10M	$-2.91M	$-2.44M	$-2.26M	$-2.39M	$-2.06M	$-1.98M	$-1.98M	$-1.70M	$-4.43M
Surprise %	-	-	-	-	0.75%	-	0.91%	1.93%	1.87%	2.20%	2.60%	1.53%	3.84%	1.36%

undefined analysts predict BTCY's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Biotricity's previous annual EBITDA (undefined) of $NaN.

Biotricity Net Income Forecast

	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1
Net Income	-	-	-	-	$-3.69M	-	$-4.69M	$-4.72M	$-4.86M	$-4.88M	$-5.62M	$-5.97M	$-11.71M	$-5.66M
Avg Forecast	$21.84M	$19.02M	$-5.10M	$-6.23M	$-4.82M	$-5.81M	$-7.65M	$-7.65M	$-6.59M	$-9.35M	$-8.50M	$-11.62M	$-11.90M	$-6.28M
High Forecast	$21.84M	$19.02M	$-5.10M	$-6.23M	$-4.82M	$-5.81M	$-7.65M	$-7.65M	$-6.59M	$-9.35M	$-8.50M	$-11.62M	$-11.90M	$-5.03M
Low Forecast	$21.84M	$19.02M	$-5.10M	$-6.23M	$-4.82M	$-5.81M	$-7.65M	$-7.65M	$-6.59M	$-9.35M	$-8.50M	$-11.62M	$-11.90M	$-7.54M
Surprise %	-	-	-	-	0.77%	-	0.61%	0.62%	0.74%	0.52%	0.66%	0.51%	0.98%	0.90%

Biotricity's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. BTCY's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Biotricity SG&A Forecast

	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1
SG&A	-	-	-	-	$3.49M	-	$3.08M	$4.78M	$4.88M	$4.88M	$5.92M	$3.65M	$5.68M	$4.66M
Avg Forecast	$11.77M	$10.42M	$10.41M	$9.76M	$10.74M	$10.09M	$8.46M	$7.81M	$8.26M	$7.12M	$6.85M	$6.84M	$5.88M	$5.21M
High Forecast	$11.77M	$10.42M	$10.41M	$9.76M	$10.74M	$10.09M	$8.46M	$7.81M	$8.26M	$7.12M	$6.85M	$6.84M	$5.88M	$5.21M
Low Forecast	$11.77M	$10.42M	$10.41M	$9.76M	$10.74M	$10.09M	$8.46M	$7.81M	$8.26M	$7.12M	$6.85M	$6.84M	$5.88M	$5.21M
Surprise %	-	-	-	-	0.32%	-	0.36%	0.61%	0.59%	0.69%	0.86%	0.53%	0.97%	0.90%

Biotricity's average Quarter SG&A projection for Dec 23 is $9.76M, based on 1 Wall Street analysts, with a range of $9.76M to $9.76M. The forecast indicates a 179.92% rise compared to BTCY last annual SG&A of $3.49M (Sep 23).

Biotricity EPS Forecast

	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1
EPS	-	-	-	-	$-0.42	-	-	$-0.09	$-0.09	$-0.09	$-0.11	$-0.15	$-0.27	$-0.17
Avg Forecast	$1.54	$1.34	$-0.36	$-0.44	$-0.34	$-0.41	$-0.54	$-0.54	$-0.47	$-0.66	$-0.60	$-0.82	$-0.84	$-0.54
High Forecast	$1.54	$1.34	$-0.36	$-0.44	$-0.34	$-0.41	$-0.54	$-0.54	$-0.47	$-0.66	$-0.60	$-0.82	$-0.84	$-0.54
Low Forecast	$1.54	$1.34	$-0.36	$-0.44	$-0.34	$-0.41	$-0.54	$-0.54	$-0.47	$-0.66	$-0.60	$-0.82	$-0.84	$-0.54
Surprise %	-	-	-	-	1.24%	-	-	0.17%	0.20%	0.14%	0.18%	0.18%	0.32%	0.31%

According to undefined Wall Street analysts, Biotricity's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to BTCY previous annual EPS of $NaN (undefined).

Biotricity Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
BJDX	Bluejay Diagnostics	$0.10	$10.00	9900.00%	Buy
BTCY	Biotricity	$0.37	$4.00	981.08%	Buy
TELA	TELA Bio	$3.06	$12.50	308.50%	Buy
DCTH	Delcath Systems	$9.41	$22.00	133.79%	Buy
MXCT	MaxCyte	$3.55	$8.00	125.35%	Buy
NARI	Inari Medical	$50.77	$66.11	30.21%	Buy
CVRX	CVRx	$14.20	$16.33	15.00%	Buy
HSCS	Heart Test Laboratories	$2.70	$3.00	11.11%	Buy
CLPT	ClearPoint Neuro	$10.95	$12.00	9.59%	Buy
SRDX	Surmodics	$38.17	$39.50	3.48%	Buy

BTCY Forecast FAQ

Is Biotricity a good buy?

Yes, according to 1 Wall Street analysts, Biotricity (BTCY) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 100.00% of BTCY's total ratings.

What is BTCY's price target?

Biotricity (BTCY) average price target is $4 with a range of $4 to $4, implying a 981.08% from its last price of $0.37. The data is based on 1 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Biotricity stock go up soon?

According to Wall Street analysts' prediction for BTCY stock, the company can go up by 981.08% (from the last price of $0.37 to the average price target of $4), up by 981.08% based on the highest stock price target, and up by 981.08% based on the lowest stock price target.

Can Biotricity stock reach $1?

BTCY's average twelve months analyst stock price target of $4 supports the claim that Biotricity can reach $1 in the near future.

What are Biotricity's analysts' financial forecasts?

BTCY's analysts financial forecasts for the fiscal year (Mar 2024) are as follows: average revenue is $12.6M (high $12.6M, low $12.6M), average EBITDA is $-11.847M (high $-11.847M, low $-11.847M), average net income is $-21.963M (high $-21.963M, low $-21.963M), average SG&A $41M (high $41M, low $41M), and average EPS is $-1.55 (high $-1.55, low $-1.55).

Did the BTCY's actual financial results beat the analysts' financial forecasts?

Based on Biotricity's last annual report (Mar 2023), the company's revenue was $9.64B, beating the average analysts forecast of $9.73M by 98999.54%. Apple's EBITDA was $-15.41B, beating the average prediction of $-9.145M by 168404.42%. The company's net income was $-19.534B, beating the average estimation of $-31.244M by 62420.56%. Apple's SG&A was $17.62B, beating the average forecast of $31.65M by 55578.81%. Lastly, the company's EPS was $-376, beating the average prediction of $-2.205 by 16949.89%. In terms of the last quarterly report (Sep 2023), Biotricity's revenue was $2.89M, missing the average analysts' forecast of $3.3M by -12.38%. The company's EBITDA was $-2.321M, missing the average prediction of $-3.103M by -25.20%. Biotricity's net income was $-3.691M, missing the average estimation of $-4.818M by -23.39%. The company's SG&A was $3.49M, missing the average forecast of $10.74M by -67.52%. Lastly, the company's EPS was $-0.42, beating the average prediction of $-0.34 by 23.53%